LifeHealth LLC has acquired the IRMA TruPoint Blood Analysis System, according to the company.
The IRMA TruPoint system was the first device to bring laboratory grade blood gas analyses to the patient bedside and continues to offer an accurate and reliable menu of blood analytes. With room temperature stored single-use analysis cartridges, the IRMA TruPoint system is an accurate, low maintenance device.
The system measures a wide variety of the most critical and highest test volume parameters for use in a multitude of distributed patient care settings. The system’s test menu includes blood gases, electrolytes, and additional clinical chemistry test panels that are delivered within two minutes with lab quality accuracy.
LifeHealth plans to continue to build on the foundation of the IRMA TruPoint product line and continue the development of its proprietary new measures that the company believes will have a significant impact on improving health.
In addition to the IRMA TruPoint product line, the acquisition gives LifeHealth a fully staffed world-class manufacturing and R&D facility and a foundation of business that will propel LifeHealth forward. LifeHealth has been developing a proprietary advanced point-of-care panel of analytes that will have major health implications. The acquisition provides the commercial infrastructure to bring this new measure to market efficiently.
“We are very pleased to acquire such meaningful assets and expertise, which allows us to advance our objective of providing diagnostic technology that helps save lives and improve the quality of care in urgent settings,” said Mike Sinsheimer, CEO of LifeHealth.
Scott Blomberg, president and COO of LifeHealth, added, “As one of the early members of the pioneering IRMA TruPoint team and the leader of the LifeHealth development efforts, I am pleased to bring these two teams together to form one highly capable organization. We are excited to leverage the strengths of the IRMA TruPoint product line and the new LifeHealth analytes to provide better diagnostic information to clinicians.”